This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
- ↵* Corresponding author; email: michelle.butina{at}hsc.wvu.edu
Abstract
Biomarkers, or biological markers, have been tested in the clinical laboratory for decades. More recently, there has been a surge in research studies aimed at identifying biomarkers of infection and inflammation. One of the foremost motivators in this expansion of research is the quest to find ideal biomarkers for sepsis. Traditional, yet still relevant, laboratory markers of infection and inflammation consist of the white blood cell count, erythrocyte sedimentation rate, and C-reactive protein. Newer biomarkers that are currently available in the clinical laboratory and used for the evaluation of sepsis include lactate and procalcitonin, while two promising emergent biomarkers for the evaluation of sepsis, pentraxin 3 and presepsin, are presented. Beyond sepsis, promising emergent biomarkers for chronic wound infections, pneumonia, and invasive fungal infections are also discussed.
- Received July 16, 2019.
- Revision received January 9, 2020.
- Accepted January 17, 2020.
- Published by American Society for Clinical Laboratory Science